Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Share-based Compensation (2016 - 2025)

Agios Pharmaceuticals' Share-based Compensation history spans 14 years, with the latest figure at $14.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 29.54% year-over-year to $14.1 million; the TTM value through Dec 2025 reached $52.6 million, up 22.65%, while the annual FY2025 figure was $52.6 million, 22.65% up from the prior year.
  • Share-based Compensation reached $14.1 million in Q4 2025 per AGIO's latest filing, up from $12.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $15.5 million in Q1 2022 to a low of $9.1 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $12.1 million, with a median of $11.6 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: crashed 34.63% in 2023, then rose 29.54% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $11.6 million in 2021, then decreased by 1.34% to $11.5 million in 2022, then increased by 20.49% to $13.8 million in 2023, then dropped by 21.07% to $10.9 million in 2024, then increased by 29.54% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Share-based Compensation are $14.1 million (Q4 2025), $12.4 million (Q3 2025), and $14.7 million (Q2 2025).